Product Design, Manufacturing & Innovation Resources

최신 출판물 – 장수 과학 관련 특허

Longevity Science

팁: 아래 선택 항목 외에도, 저희가 제공하는 두 개의 전체 데이터베이스를 검색하고 필터링할 수 있습니다.

> 무료 간행물 검색 도구 < 저자, 주제, 키워드, 날짜 또는 저널별로 검색.

> 무료 특허 검색 도구 < 유럽 ​​특허청의 영문 특허를 참조하십시오.

Longevity science
Advancements in longevity science aim to enhance healthspan and 수명 through innovative interventions targeting the biological mechanisms of aging.

Longevity Science investigates the biological mechanisms underlying aging and age-related decline, focusing on cellular senescence, telomere dynamics, epigenetic alterations, mitochondrial function, and systemic inflammation. This multidisciplinary field integrates 분자생물학, genetics, pharmacology, and bioinformatics to identify interventions that extend healthspan and lifespan. Research spans senolytic compounds, caloric restriction mimetics, stem cell therapies, and epigenetic reprogramming, aiming to delay or reverse physiological deterioration. The following compilation presents the latest peer-reviewed publications and patents, reflecting advances in biomarkers of aging, geroprotective agents, and translational approaches targeting fundamental aging processes.

본 자료는 노화, 텔로미어, 장수 과학, 칼로리 제한, 자가포식, 미토콘드리아 기능 장애, 후성유전학적 시계, 노화 방지제, 노화 세포 제거제, 줄기세포 치료, 산화 스트레스, DNA 복구, 단백질 항상성, 염증성 노화, mTOR 억제, 시르투인, 장수 유전자, 메트포르민, 라파마이신, 세포 재프로그래밍, 노화 관련 질환, 노화 바이오마커, 기능성 식품, 수명 연장, 건강 수명, 텔로머라제 활성화, 일주기 리듬, 당화, 신경 퇴행, 호르메시스 및 후성유전학 등 다양한 주제로 분류 및 집중적으로 발표된 전 세계 영어 논문 및 특허를 엄선하여 정리한 것입니다.

Methods of reducing host cell proteins in recombinant protein production

Patent published on the 2026-06-11 in WO under Ref WO2026122415 by MERCK SHARP & DOHME LLC [US] (Chang Meiping [us], Sahoo Ansuman [us], Madabhushi Sri Ranganayaki [us], Tsukidate Taku [us], Li Xuanwen [us])

Abstract: Provided herein are methods of reducing expression of host cell proteins during a mammalian cell culture process using peroxisome proliferator–activated receptor γ (PPARγ) modulator and/or an autophagy-inducing compounds.[...]


Our summary: Methods are described to reduce host cell protein expression during mammalian cell culture. The approach utilizes PPARγ modulators and autophagy-inducing compounds. These strategies aim to enhance the purity of recombinant proteins.

host cell proteins, recombinant protein production, PPARγ modulator, autophagy-inducing compounds

Patent

Carboxamide compounds as a selective epac2 activator

Patent published on the 2026-06-04 in US under Ref US20260152492 by CELAGENEX RES INDIA PVT LTD [IN] (Samant Rajaram [in], Tongra Manoj [in])

Abstract: [0000] The present invention relates to novel carboxamide compounds of Formula-I, which act as potent activators of Exchange Protein Activated by cAMP 2 (EPAC2). The invention further provides a sustainable, one-pot process for the preparation of these EPAC2-activating compounds of Formula-I. Accordingly, the compounds are useful in the treatment and management of EPAC2-associated therapeutic conditions including neurological disorders, synaptic dysfunction, cognitive impairment, and neurodegene[...]


Our summary: Novel carboxamide compounds activate EPAC2 effectively. They are synthesized through a sustainable one-pot process. These compounds target conditions related to cognitive impairment and neurodegeneration.

Carboxamide, EPAC2, activator, neurological disorders

Patent

Compositions and methods for adeno-associated (aav) virus dnase expression

Patent published on the 2026-05-28 in WO under Ref WO2026111749 by CLS THERAPEUTICS LLC [US] (Genkin Dmitry [us], Tetz George [us], Grant Logan [us], Ian Alexander [us])

Abstract: The invention relates to gene therapy, and more specifically, to AAV gene therapy vectors containing a novel chimeric deoxyribonuclease (DNase) protein transgene and methods of treating ailments such as cancer and neurodegeneration.[...]


Our summary: The invention involves AAV gene therapy vectors with a chimeric DNase protein transgene. It aims to treat conditions like cancer and neurodegeneration. The method enhances therapeutic efficacy through targeted gene delivery.

AAV, gene therapy, DNase, chimeric protein

Patent

Method for determining the sensitivity of a cancer to pd-1/pd-l1 therapy

Patent published on the 2026-05-28 in WO under Ref WO2026109721 by ASSIST PUBLIQUE HOPITAUX DE PARIS [FR] (Granier ClÉmence [fr], Paillaud Elena [fr], Gonnin CÉcile [fr])

Abstract: The present invention belongs to the field of disease therapy, and more specifically to the field of cancer therapy. In particular, the present invention belongs to a method for determining the sensitivity of a condition, preferably cancer, to a therapeutic agent and/or a method for determining whether a subject suffers from immune ageing and/or immunosenescence.[...]


Our summary: The invention provides a method to assess cancer sensitivity to PD-1/PD-L1 therapy. It focuses on determining the effectiveness of therapeutic agents for cancer treatment. Additionally, it evaluates whether a subject experiences immune aging or immunosenescence.

cancer therapy, PD-1, PD-L1, immune senescence

Patent

System and method for predictive modeling of cellular systems

Patent published on the 2026-05-28 in US under Ref US20260146990 by GEORGE MASON UNIV [US] (Kabbani Nadine [us], Sinclair Patricia [us], Jeffries William [us])

Abstract: [0000] A system and method for predictive modeling of cellular systems assesses compound effectiveness on cellular metabolic and inflammatory states. Cellular samples are exposed to metabolic MRX sensors detecting oxidative stress, reporting cytoskeletal organization, or monitoring mitochondrial morphology, dynamics, or compartment-specific redox activity. Images of MRX sensor-labeled samples are captured using an imaging device and analyzed by trained predictive models to determine compound imp[...]


Our summary: The system assesses compound effectiveness on cellular metabolic and inflammatory states. It utilizes metabolic MRX sensors and imaging devices to analyze cellular samples. Predictive models classify treatment conditions and enable compound ranking for drug screening and toxicity assessment.

predictive modeling, cellular systems, oxidative stress, drug screening

Patent

Lactococcus lactis subsp. lactis strain and its uses

Patent published on the 2026-05-27 in EP under Ref EP4748921 by NEA THEA 7 S L [ES] (GarcÍa MartÍn Elsa [es], De La Cruz SÁnchez Rebeca [es], MartÍn Diana Ana BelÉn [es], Rico Bargues Daniel [es], Requena Rolania Teresa [es], Olmo LÓpez RocÍo [es], MartÍn Quijada Narciso [es], Monte VÁzquez Enrique [es])

Abstract: The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and/or reduction of hypertension, or as a food composition or nutraceutical.[...]


Our summary: The invention focuses on Lactococcus lactis subsp. lactis CECT 31096 and its components. It highlights its potential uses in preventing or reducing hypertension. Additionally, it discusses applications in food compositions and nutraceuticals.

Lactococcus lactis, hypertension, metabolites, nutraceutical

Patent

Capabilities and biophysical challenges at clinical 7T scanners

Published on 2026-04-09 by @MIT

Abstract: AbstractSub-millimeter resolution functional magnetic resonance imaging (fMRI) at ultra-high field (≥ 7T) has offered an unprecedented opportunity to probe mesoscopic computations at a columnar or laminar level. However, its application has been primarily restricted to the neocortex. Inferior brain regions, particularly the hippocampus (HC), are challenging targets for laminar fMRI. Recent developments in acquisition methods have shown the feasibility of laminar recordings in the HC using grad[...]


Our summary: This study explores the capabilities of 7T MRI for laminar fMRI in the hippocampus. It demonstrates the optimization of VASO to reduce venous bias and improve signal quality. The findings support the use of advanced acquisition methods to investigate memory retrieval mechanisms at a submillimeter resolution.

7T MRI, fMRI, VASO, hippocampus

Publication

Retinal nerve fibre layer thickness reflects characteristics of brain grey and white matter

Published on 2026-04-02 by @MIT

Abstract: AbstractThe retina is an optically accessible part of the central nervous system. Using high-resolution optical coherence tomography, we explored the relationship between retinal thickness and structural features of the brain obtained with magnetic resonance imaging. We hypothesized that there are associations between circumpapillary (i.e., around optic disc) retinal nerve fibre layer thickness and structural features of (i) brain areas and pathways related to visual information processing and ([...]


Our summary: Circumpapillary retinal nerve fibre layer thickness is associated with visual cortex grey matter density and optic radiation fractional anisotropy. Cardiovascular risk factors impact brain structure, but their correlation with retinal thickness was not significant. Further studies are needed to explore the relationship between eye and brain health in the context of neurodegenerative diseases.

retinal nerve fibre layer, brain structure, optical coherence tomography, cardiovascular risk factors

Publication

다룬 주제: 장수 과학, 건강 수명, 수명, 생물학적 메커니즘, 세포 노화, 텔로미어 역학, 후성유전적 변화, 미토콘드리아 기능, 전신 염증, 분자 생물학, 유전학, 약리학, 생물정보학, 노화 세포 제거 화합물, 칼로리 제한 모방제, 줄기세포 치료, 후성유전적 재프로그래밍, 노화 바이오마커, 노화 방지제, ISO 22118, ISO 22120, ISO 22000, ISO 9001 및 ISO 14001.

역사적 맥락

2000
2003
2010
2013-09-24
2000
2002
2010
2013

(날짜를 알 수 없거나 관련이 없는 경우, 예를 들어 "유체역학"의 경우, 주목할 만한 등장 시기를 대략적으로 추정하여 제공합니다.)

고화질 이미지 및 다운로드는 등록된 회원에게만 100% 무료로 제공됩니다.

> 로그인 <